BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao L, Zhu L, Cheng L. ncRNA-Regulated LAYN Serves as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma: A Bioinformatics Analysis. BioMed Research International 2022;2022:1-23. [DOI: 10.1155/2022/5357114] [Reference Citation Analysis]
2 Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00317-x] [Reference Citation Analysis]
3 Li S, Yin S, Ding H, Shao Y, Zhou S, Pu W, Han L, Wang T, Yu H. Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Prolif 2022;:e13346. [PMID: 36229407 DOI: 10.1111/cpr.13346] [Reference Citation Analysis]
4 McHenry S, Zong X, Shi M, Fritz CDL, Pedersen KS, Peterson LR, Lee JK, Fields RC, Davidson NO, Cao Y. Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. Hepatol Commun 2022. [PMID: 36221229 DOI: 10.1002/hep4.2073] [Reference Citation Analysis]
5 Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, Bong SHS, Win KM, Bwa AH, Lim WH, Tan DJH, Zeng RW, Chew N, Teng ML, Siddiqui MS, Oben JA, Sanyal AJ, Wai-sun Wong V, Noureddin M, Muthiah M. A Meta-Analysis on Associated Risk of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.10.007] [Reference Citation Analysis]
6 Vaz J, Strömberg U, Midlöv P, Eriksson B, Buchebner D, Hagström H. Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: A nationwide cohort study of 3473 patients. J Intern Med 2022. [PMID: 36166276 DOI: 10.1111/joim.13570] [Reference Citation Analysis]
7 Guan X, Chen Y, Xu H. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. European Journal of Radiology 2022;154:110450. [DOI: 10.1016/j.ejrad.2022.110450] [Reference Citation Analysis]
8 Ng CH, Nah B, Kaewdech A, Aung HB, Mak L, Kulkarni AV, Muthiah M. Factors Associated with Risk of NAFLD and Progression in Multiethnic Asians. A Latent Class and Machine Learning Analysis.. [DOI: 10.21203/rs.3.rs-1968295/v1] [Reference Citation Analysis]
9 Liu X, Xie W, Meng S, Kang X, Liu Y, Guo L, Wang C. Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. Cells 2022;11:2654. [DOI: 10.3390/cells11172654] [Reference Citation Analysis]
10 Huang Y, He Z, Manyande A, Feng M, Xiang H. Nerve regeneration in transplanted organs and tracer imaging studies: A review. Front Bioeng Biotechnol 2022;10:966138. [DOI: 10.3389/fbioe.2022.966138] [Reference Citation Analysis]
11 Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang J, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.942753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Craciun A, Cortez-pinto H. Alarming increase of NASH as cause of liver cancer. Cell Reports Medicine 2022;3:100723. [DOI: 10.1016/j.xcrm.2022.100723] [Reference Citation Analysis]
13 Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, Ghobrial RM. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Current Oncology 2022;29:4267-4273. [DOI: 10.3390/curroncol29060341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open 2022;5:e2219407. [PMID: 35767258 DOI: 10.1001/jamanetworkopen.2022.19407] [Reference Citation Analysis]
15 Liu L, Liao R. Clinical features and outcomes of NAFLD-related hepatocellular carcinoma. The Lancet Oncology 2022;23:e243. [DOI: 10.1016/s1470-2045(22)00272-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tan DJH, Ng CH, Muthiah MD, Loomba R, Huang DQ. Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors' reply. The Lancet Oncology 2022;23:e244. [DOI: 10.1016/s1470-2045(22)00265-0] [Reference Citation Analysis]
17 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
18 Spiers J, Brindley JH, Li W, Alazawi W. What’s new in non-alcoholic fatty liver disease? Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]